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Abstract
The lymphogranuloma venereum (LGV) outbreak described in the Netherlands in 2003, increased the interest in the genotyping of
Chlamydia trachomatis. Although international surveillance programmes were implemented, these studies slowly decreased in the following
years. Now data have revealed a new accumulation of LGV cases in those European countries with extended surveillance programmes.
Between March 2009 and November 2011, a study was carried out to detect LGV cases in Madrid. The study was based on screening of
C. trachomatis using commercial kits, followed by real-time pmpH-PCR discriminating LGV strains, and ﬁnally ompA gene was sequenced
for phylogenetic reconstruction. Ninety-four LGV infections were identiﬁed. The number of cases increased from 10 to 30 and then to 54
during 2009–2011. Incidence of LGV was strongly associated with men who have sex with men; but in 2011, LGV cases were described in
women and heterosexual men. Sixty-nine patients were also human immunodeﬁciency virus (HIV) positive, with detectable viral loads at
the moment of LGV diagnosis, suggesting a high-risk of co-transmission. In fact, in four patients the diagnosis of HIV was simultaneous
with LGV infection. The conventional treatment with doxycycline was prescribed in 75 patients, although in three patients the treatment
failed. The sequencing of the ompA gene permitted identiﬁcation of two independent transmission nodes. One constituted by 25
sequences identical to the L2b variant, and a second node including 37 sequences identical to L2. This epidemiological situation
characterized by the co-circulation of two LGV variants has not been previously described, reinforcing the need for screening and
genotyping of LGV strains.
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Introduction
Lymphogranuloma venereum (LGV) cases have rarely been
diagnosed in industrialized countries, but in 2003 a small LGV
outbreak was described in the Netherlands among men who
have sex with men (MSM) [1]. Later, further outbreaks were
rapidly communicated across many European countries [2]. As
a consequence, alerts about the increase in LGV cases were
communicated for the European Centre for Disease Prevention
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and Control and the CDC [3,4] and surveillance programmes
were implemented in several countries such as the Nether-
lands [5] and the UK (www.hpa.org.uk). During subsequent
years, many more countries reported cases of LGV in Europe,
Australia and the USA [6,7]. However, since 2009 the alarm
has decreased and some authors predicted that LGV
outbreaks would decline in the near future [8], even though
new European regions continued to detect isolated cases of
LGV in subsequent years [9]. There is limited epidemiological
information about the evolution of the international outbreak,
as only a few national surveillances are implemented and the
published data refer only to high-risk populations. However, a
new accumulation of cases is currently occurring in some
countries with extended surveillance programmes. For
instance, the UK Health Protection Agency (www.hpa.org.
uk) and a Spanish region have detected an increase of ~ 115%
in the last 2 years [10]. More worryingly, in the Netherlands
this increase has reached 265% in the ﬁrst 6 months of 2012
[11]. Moreover, the British Columbia Centre for Disease
Control (www.bccdc.ca) and the National System of Epidemi-
ological Surveillance of Mexico (www.dgepi.salud.gob.mx) have
also described a sustained increase of LGV cases in recent
years.
Since the description of the ﬁrst LGV cases, researchers
realized that the genotyping of LGV should be improved,
because LGV spread could be linked to delay in diagnosis [12]
and inappropriate duration of antibiotic treatment [13].
Moreover, strong association between LGV and human
immunodeﬁciency virus (HIV) [3,4], and other sexually
transmitted infections (STI) such as syphilis and hepatitis C
virus have been documented [14]. Unfortunately, many
laboratories still do not have genetic tools to discriminate
LGV genovars from other genovars of Chlamydia trachomatis,
suggesting that the cases of LGV could be underestimated
[15]. In this epidemiological situation there are several
reasons for increasing efforts for correct identiﬁcation of
LGV genovars.
Real-time PCR techniques were developed based on
internal deletion of the pmpH gene [16], facilitating LGV
surveillance [17]. The current recommendation for the
diagnosis and surveillance of LGV suggests a screening stage
based on commercial kits to detect all C. trachomatis infections,
followed by real-time pmpH-PCR to discriminate between
LGV and non-LGV strains and ﬁnally ompA gene sequencing as
the most appropriate approach for phylogenetic reconstruc-
tion [18]. The aim of the present study was to detect the
presence of LGV cases in Madrid, and if these genotypes were
detected the sequencing of ompA gene could permit phyloge-
netic reconstructions to ﬁnd a reason for the hypothetical
increase in the number of LGV cases.
Methods
Collection of clinical strains
Two STI Units in Madrid, Spain, were involved in the present
study. From March 2009 to November 2011 a total of 13 585
samples were collected from 8407 attendees, who came
voluntarily for suspected STI as a consequence of sexual risk
behaviour. The age range was 14–79 years; 4190 were women
(49.8%), 59 (0.7%) were transsexuals and 4148 (49.5%) were
men, of whom 3282 (78.9%) were MSM.
The criteria for collecting samples were based on clinical
symptoms or sexual risk behaviours with or without symp-
toms. In women, the samples were obtained from cervix to
rectum in the case of anal sex, in men, from rectum to urethra.
The distribution of 13 585 samples was rectal (n = 3185),
urethral (n = 2420), cervical (n = 5462) and pharyngeal
(n = 2518). All samples were cultured or analysed for the
presence of microorganisms related to sexually transmitted
diseases, including C. trachomatis, Neisseria gonorrhoeae, Trepo-
nema pallidum and HIV.
This study was approved by the Ethics Committee of
Ramon y Cajal Hospital.
Laboratory diagnosis of C. trachomatis and LGV-serovars
Screening of C. trachomatis was based on two molecular
commercial tests: Abbott Real Time CT/NG (Abbott Labora-
tories, Des Plaines, IL, USA) was performed in one STI Unit, and
BD-ProbeTecTM ET CT/GC (Becton Dickinson Diagnostic
Systems, Sparks, MD, USA) in the second STI Unit, according
to the manufacturer’s recommendations. The samples yielding
positive ampliﬁcations for C. trachomatis were anonymized and
sent in a suitable transportmedium from the diagnostic kit to the
second laboratory for genotyping. In the second laboratory, a
new DNA extraction was performed using Nuclisens easyMag
(BioMerieux, Inc, Durham, NC, USA). Then, a speciﬁc real-time
PCR to C. trachomatis pmpH gene where a 36 base-pair (bp)
deletion occurs, was performed in all LGV serovars, as
previously described [19,20]. In brief, a fragment of 60 bp was
ampliﬁed using the primers LGV-F: 5′-CTGTGCCAACCTCATC
ATCAA-3′ and LGV-R 5′-AGACCCTTTCCGAGCATCACT-3′
and as probe 5′-FAM-CCGCCTGCTCCAACAGTTAGTGATG-
BHQ1 [21]. A complete description of the real-time PCR condi-
tions can be found in the original publications [16,20]. Moreover,
a speciﬁc detection of the ompA gene was performed in parallel
with pmpH evaluation. An amplicon of 69 bp, between 124 and
196 positions, was detected. The combinations of primers and
probe are also previously described [16]. Reference strain of
C. trachomatis ATCC VR-902B was used as positive control for
LGV in each real-time PCR assay. A presumptive diagnosis of
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LGV infection was considered when the pmpH-PCR yielded
positive ampliﬁcation.
Sequence and phylogenetic analyses
To perform the phylogenetic analyses, 858 bp of ompA gene,
encoding the major outer membrane protein, were sequenced
in all LGV cases. The primers ompA-F: 5′-ATGAAA AAACTCT
TGAAATCGG-3′ and ompA-R: 5′-ACTGTAACTGCGTATTT
GTCTG-3′ were used following the previously published
recommendations [22]. Sequences from all C. trachomatis LGV
available at the National Center for Biotechnology database
were downloaded (http://www.ncbi.nlm.nih.gov), including at
least one representative of LGV variants described (Fig. 2).
Sequences were edited with CHROMAS 2.33 software and aligned
using CLUSTALX version 2.0 followed by manual editing. To
discard sequencing and alignment errors all nucleotide
sequences were translated to proteins to assure the absence
of nonsense mutations. The sequences of ompA gene from
detected LGV strains were used to reconstruct amedian-joining
network 4.6.1.0 (http://www.ﬂuxus-technology.com).
Nucleotide sequence accession numbers
The ompA sequences described in this work have been
deposited in GenBank with the accession numbers between:
JX971886 and JX971960.
Statistical analysis
For exploring the associations between nominal-by-nominal
measures (symptoms or not symptoms), chi-squared test or
Fisher’s exact test, when sample size was small, were used.
Results
Characterization of the recent LGV outbreak in Madrid
A total of 1239 of 13 585 specimens (9.1%) yielded a positive
C. trachomatis result. Based on the pmpH gene ampliﬁcation 94/
1239 (7.6%) were further identiﬁed as LGV. Overall, LGV cases
increased during the study period (120%, 2009–2010; 80%
2010–2011) (Fig. 1). They were more often detected in MSM
(87/94, 92.5%), but in 2011, seven cases were diagnosed in the
heterosexual population (four men and three women), suggesting
that the outbreak is far from being controlled. As to country of
origin, 56% were Spaniards, 37.3% were South Americans, 6.6%
were non-Spanish Europeans and 1.3% were from other regions.
Identiﬁcation of two transmission clusters responsible for the
LGV outbreak
In 75/94 LGV strains an 858-bp fragment of the ompA gene was
successfully sequenced. In 25/75 (33.3%) sequences were
identical to ompA from L2b, 37/75 (49.3%) were identical to
L2/L2f and the remaining 13/75 sequences (17.3%) were
variants derived from them. The network phylogenetic tree
revealed two major transmission nodes (Fig. 2). A node was
constituted by 25 sequences identical to L2b, which has been
implicated in the LGV worldwide outbreak [23]. The second
node of transmission consisted of 37 sequences identical to
the L2/L2f variant [21,24]. Moreover, ten new genotypes,
carrying amino acid changes not previously described derived
from L2/L2f and L2b, were also identiﬁed. According to the
numbering of L2/434 strain, six non-synonymous substitutions
were found in the variable domain-I (A91T and T92A) and
variable domain-II (N162S, H165Y, L173I and D180Y), where
major neutralizing and serotyping antigenic determinants are
located [25]. Moreover, several non-synonymous substitutions
were selected in more than one case (such as Q75R, D71H
and D180Y), suggesting positive selection or recombination
events (Fig. 2).
Clinical epidemiological features of LGV cases
As to anatomic site of origin, 419/3185 (13.2%) rectal samples
yielded positive C. trachomatis ampliﬁcation, from which 82
(19.2%) were identiﬁed as LGV. Ten of 338 (2.6%) positive
urethral samples, and two of the 332 (0.6%) positive cervical
samples were also LGV genovars; no LGV strains were
identiﬁed in pharyngeal samples (Table 1). Of the 94 LGV
patients, 69 (73.4%) were HIV positive; this percentage would
reach 79.3% (69/87) if only MSM were evaluated. Among 51/69
HIV-positive patients with an available viral load test, 80% had a
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FIG. 1. Temporal distribution of lymphogranuloma venereum (LGV)
cases detected during the period between March 2009 and November
2011. The detection of LGV strains was based on the 36 base-pair
deletion in the pmpH gene according to Schaeffer and Henrich [16].
Moreover, the pmpH gene was sequenced in 45 Chlamydia trachomatis
clinical isolates from LGV and non-LGV samples, conﬁrming in all cases
the correct classiﬁcation of LGV detected. Asterisk shows the date of
the ﬁrst case of LGV in a heterosexual man and also the ﬁrst cervical
sample in our study.
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FIG. 2. Phylogenetic network analysis from 75 lymphogranuloma venereum (LGV) strains identiﬁed during the period of study based on ompA/
major outer membrane protein. Two major nodes are differentiated, corresponding to L2/L2f and L2b variants, which differ in a single amino acid
change between them. (a) Network analysis based on nucleotide sequences. Asterisk indicates short sequences. Italics numbers inside the circles
indicate the number of strains included in each node and arabic numbers on the lines indicate the number of mutations in each arm. (b) Network
analysis using the corresponding amino acid sequences. Amino acidic changes are indicated in each arm referred to L2/434/Bu strain (AM884176).
The sequenced fragment was 858 base pairs (starting in the ﬁrst 20 nucleotides in the leader peptide and ending in the 1106 position). Italics changes
indicate common changes to more than one variant. The L2e and L2 sequences are not represented because the fragment used in the analysis is
identical to L2f. The numerical differences observed in L2f and L2b nodes between nucleotide and amino acid networks correspond to synonymous
mutations. Grey colour corresponds to reference sequences downloaded from GenBank. The ﬁlled black dots correspond to non-sampled or extinct
ancestral genotypes. The access numbers of reference sequences used in the phylogenetic network were: L2a (AF30485); L2(AM884176); L2b
(AM884177); L2c (NC_015744); L2d (EF460797); L2e (EF460798); L2f (EU676181); L2g (EU676180).
TABLE 1. Clinical characteristics of 94 patients with a diagnosis of lymphogranuloma venereum (LGV), according to origin of the
samples
Origin
Analysed
samples
C. trachomatis
positive
LGV
positive
HIV positive
(% detectable
viral load)
STI
concomitanta Clinical characteristics Symptoms (%) Signs (%)
Rectal 3185 419 82b 66 (+1 unknown)c
(40/50 detectable
viral load)
42 Purulent discharge 32.9 53.6
dPain/Tenesmus 60
Bleeding 43.9 23.1
Ulcer 8.5 23.1
Mucus 4.8 14.6
Diarrhoea 7.3
Itching 8.5
None 10.9
Urethral 2420 388 10e 3 (+2 unknown)
(1/1 detectable
viral load)
5 fPurulent discharge 6
Ulcer + inguinal
lymphadenopathy
2
Lymphadenopathy 1
Balanitis 1
None 0
Cervicalg 5462 322 2h 1 unknown
Pharyngeal 2518 100 0
Total 13585 1239 94 69 47
C. trachomatis, Chlamydia trachomatis; HIV, human immunodeﬁciency virus; STI, sexually transmitted infection.
aSTIs, non-HIV, included were syphilis (25 cases), gonorrhoea (13 cases), C. trachomatis non-LGV (two cases), genital herpes (one case) and hepatitis B virus (one case).
bOnly one case was described in a woman.
cThe viral load was not measured in all patients with HIV.
dSymptoms and signs are shown together.
eSix patients were men who had sex with men.
fFour of these patients presented gonococcal urethritis.
gClinical characteristics are not shown because the number of LGV-positive patients was very low.
hOne patient was asymptomatic.
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detectable HIV viral load, the mean value being 4.86 log10
(Table 1). These worrying data suggest a high risk of co-
transmission; in fact, in four patients the diagnosis of HIV was
simultaneous to LGV infection. In our series, 50% of the
patients also presented other STIs concurrently (Table 1) even
though, depending on the location, the prevalence of main
pathogens was different. Syphilis (25/82 rectal LGV cases) and
gonorrhoea (13/82 cases) were more frequently identiﬁed in
rectal samples.
Clinical symptoms present in 89.3% (84/94) of patients,
ranged between severe proctitis (rectal bleeding) to mild
(itching and diarrhoea). Moreover, ten asymptomatic cases
were detected in rectal (nine cases) and cervical samples.
Those patients carrying the L2b variant presented bleeding and
pain more frequently (Table 2) than the group with L2/L2f
(p <0.009 and p <0.04, respectively). Furthermore, in general,
the patients carrying the L2/L2f variant reported less severe
clinical features (or no symptoms) than patients with L2b,
except for anal ulcers.
According to all guidelines [13,26], doxycycline (100 mg/
12 h for 3 weeks) was prescribed in 75 patients (80%). The
criterion for prescription of doxycycline was clinical suspicion
of LGV infection (acute symptoms of proctitis). Sixteen
individuals without relevant clinical ﬁndings or who were
asymptomatic were initially treated with a single dose of
azithromycin 1 g. In this group, if the genotyping result
corresponded to LGV, a second round of conventional
treatment with doxycycline was started. In two patients,
C. trachomatis was eradicated after the initial treatment with
azithromycin. Three patients did not receive antibiotic treat-
ment against C. trachomatis because it was not suspected and
the patients did not return to receive the results.
At the end of the treatment protocol 57/91 (63%) treated
patients had their disease controlled, and all except three were
negative for C. trachomatis. L2b was the variant present in
these three patients; they were treated with moxiﬂoxacin
(400 mg/day, 7 days) [27]. Finally, in these cases, after
moxiﬂoxacin treatment the C. trachomatis PCR became neg-
ative.
Discussion
The ﬁrst LGV case described in Spain was detected in the MSM
partner of a man diagnosed in Amsterdam [28]. Since
September 2007, new cases of LGV have continued to be
diagnosed in the northeast of Spain [10,29,30], with ﬁve cases
conﬁrmed as belonging to the L2b variant [30]. These data
would suggest that these northeast Spanish regions could have
been the putative entrance of L2b from the original outbreak
in Europe [1,23].
The surveillance and genetic characterization of LGV strains
was implemented in Madrid, although no cases had been
previously reported, leading to the identiﬁcation of 94 cases
among 13 585 analysed samples. It is worrying that in this
period the number of cases continuously increased from 10 to
30 and then to 54 cases. These data reveal an increase of
nearly 120% in 2010 and 80% in 2011 with respect to the
previous year (Fig. 1). Moreover, in the last year the outbreak
extended to women and heterosexual men, indicating the
spread towards other population groups. Similar results in two
different regions of Spain suggest a wide spread of LGV strains
during the period 2008–2011 [10]. In countries with extended
surveillance programmes, such as the Netherlands [11] and the
UK (www.hpa.org.uk), similar increases were reported. In
these countries, as in Spain [10], a bimodal dynamic of the LGV
outbreak has occurred. In fact, it is worrying that the
accumulation of LGV cases in these countries is higher now
than at the beginning of the outbreak. The reason for this
increase is unknown. The changes in sexual behaviour,
extended sexual networks and immigration ﬂows constitute
an ideal setting for the description of new outbreaks and
possibly maintenance of this infectious agent in the population
if measures such as screening and genotyping programmes are
not implemented to avoid re-establishing LGV and prevent
long-term complications [31]. These results reinforce the
necessity for maintaining the detection of LGV in surveillance
programmes.
TABLE 2. Clinical characteristics of the patients, depending
on the lymphogranuloma venereum (LGV) variants detected
L2b (%) L2/L2f (%) p
Symptoms
Purulent discharge 20 19.3 nsc
Pain 75 45 0.035
Bleeding 70 32.2 0.008
Ulcer 0 9.6
None 5 12.9 ns
Signs
Purulent discharge 55 58 ns
Bleeding 30 22.5 ns
Ulcer 25 22.5 ns
Adenopathies 0 9.6
None 5 6.4 ns
Human immunodeﬁciency virus status
Positive 80 87.1 ns
Negative 15 12.9 ns
Unknown 5 0
Hepatitis C virus status
Positive 15b 12.9 ns
Negative 65 64.5 ns
Unknown 20 22.5 ns
STIs concomitanta
Yes 60 54.8 ns
HIV, human immunodeﬁciency virus; STI, sexually transmitted infection.
Boldface numbers indicate the symptoms with statically signiﬁcant differences.
aSTIs, non-HIV, included were syphilis, gonorrhoea.
bEight HIV-positive patients with LGV in the rectal sample also carried hepatitis C
virus.
cNot signiﬁcant.
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The most outstanding factor in the LGV outbreak in Madrid
has been the identiﬁcation of two transmission nodes related to
two different LGV variants (Fig. 2). A transmission node was
constituted by 25 LGV strains belonging to L2b plus ﬁve evolved
variants derived from it [1,23]. The L2b node was found in a
similar proportion between Spaniards and South Americans. A
second node included 37 strainswith identical ompA to an L2/L2f
variant (Fig. 2). Moreover, ﬁve evolved variants were also
described as derived from the L2/L2f-node. This nodewas found
mostly in Spaniards (p <0.001), suggesting a different dynamic of
transmissionwith respect to the L2b node. The L2 strain is more
prevalent in America than other regions [32]; in fact the last
known outbreak by L2 was in 1992 in the Caribbean area [33].
Considering the high ﬂow of immigrants from South-American
countries to Spain between 2005 and 2007 and the well
documented South American–Spanish connection, a bidirec-
tional route of transmission of infectious diseases such as HIV
[34] and LGV can be expected and we could speculate that L2/
L2f arrived in Spain through the South American–Spanish route
instead of the L2b European route. These data would suggest
that the co-circulation of two LGV variants in Madrid, Spain,
could be the result of two independent introductions. It will be
interesting to determine if the accumulation of cases observed in
other countries such as the UK and the Netherlands, could be
related to the presence of L2/L2f in addition to L2b.
On the other hand, the signiﬁcant association observed
between the L2b variant and bleeding (p <0.009) and pain
(p <0.04) suggests higher virulence than L2 [35]. On the
contrary, the patients carrying L2/L2f presented less aggressive
symptomatology, suggesting that those patients with the L2/L2f
variant take longer to visit an outpatient clinic, so delaying the
diagnosis, and also favouring more transmission events. This
evolutionary strategy could provide difﬁcult and late diagnoses
and consequently higher transmission rates. This study con-
stitutes a warning for sexual health and public health
preventive strategies. Moreover, the high frequency of co-
infections, specially in the MSM group, and the high percentage
of HIV-positives with a detectable viral load at the same time
as LGV diagnosis are suggestive of a very high risk of co-
transmissions, in fact in our series four patients were
simultaneously diagnosed with LGV and HIV.
In conclusion, to our knowledge this analysis represents one
of the most comprehensive studies about the genetic charac-
terization and dynamics of transmission of a worldwide LGV
outbreak in a European city characterized by the co-circulation
of two LGV variants. LGV attentive surveillance must continue.
In this aspect, our study provides a strong contribution for the
worldwide picture of LGV molecular epidemiology by provid-
ing genetic characterization of strains and through evaluation
of LGV transmission dynamics.
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